Leukemia Cancer Market
Global Leukemia Cancer Market Size, Share & Trends Analysis Report by Type (Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, and Chronic Lymphocytic Leukemia), by Diagnose and Monitor (Blood Test, Bone Marrow Test, Imaging Test, Lymph Node Biopsy, Lumbar Puncture, and Urine Test), and by Treatment (Chemotherapy, Radiation Therapy, Targeted Therapy, Biological Therapy, and Steam Cell Therapy) Forecast Period (2022-2028) Update Available - Forecast 2024-2030
The global leukemia cancer market is anticipated to grow at a significant CAGR of 5.1% during the forecast period. The high incidence rate of blood cancers and the rise in the incidence of leukemia across the globe will drive the leukemia market. For instance, according to Leukemia & Lymphoma Society, Leukemia, lymphoma, and myeloma are expected to cause the deaths of an estimated 57,750 people in the US in 2021. These diseases are expected to account for 9.5 % of the deaths from cancer in 2021, based on the estimated total of 608,570 cancer deaths. Moreover, in 2021, 61,090 people are expected to be diagnosed with leukemia and an estimated 397,501 people are living with or in remission from leukemia in the US.
Impact of COVID-19 Pandemic on Global Leukemia Cancer Market
The havoc caused by the COVID-19 pandemic continues to disrupt daily life, but its reach goes deeper and further with mounting consequences for cancer patients who need ongoing treatment. Hospitals and clinics have shifted daily resources to cope with an influx of patients with COVID-19 disease, forcing cancer patients to weigh the potential benefit of a face-to-face visit and treatment with the risks of catching the virus. Moreover, The consequences of delayed diagnoses could be significant. An additional 6,270 cancer deaths have been predicted in Britain in the next year–a 20 percent increase–with an extra 33,890 deaths estimated in the US.
Segmental Outlook
The global leukemia cancer market is segmented based on the type, diagnosis & monitor, and treatment. Based on the type, the market is segmented into acute myeloid leukemia, chronic myeloid leukemia, acute lymphoblastic leukemia, and chronic lymphocytic leukemia. Based on the diagnose and monitor, the market is sub-segmented into the blood test, bone marrow test, imaging test, lymph node biopsy, lumbar puncture, and urine test. Based on the treatment, the market is augmented into chemotherapy, radiation therapy, targeted therapy, biological therapy, and stem cell therapy. The above-mentioned segments can be customized as per the requirements. Among the diagnose and monitor, the blood test is expected to hold a significant share in the market over the forecast period. A diagnosis of leukemia is usually made by analyzing a patient's blood sample through a complete blood count (CBC) or microscopic evaluation of the blood, or by using flow cytometry.
Global Leukemia Cancer Market Share by Treatment, 2021 (%)
The Chemotherapy Segment is Expected to Hold the Considerable Share in the Global Leukemia Cancer Market
Among the treatment segment, the chemotherapy segment is expected to hold a considerable share in the market over the forecast period. Chemotherapy may shrink patients’ cancer or slow down its growth, which supports them to live longer and diagnose their symptoms. For a small number of people with borderline resectable cancer, chemotherapy may shrink cancer enough to make surgery to remove cancer possible. According to the American Cancer Society, the II stage patients receive surgery followed by chemotherapy (60%), radiation (24%), or both (1%).
Regional Outlooks
The global leukemia cancer market is further segmented based on geography including North America (the US, and Canada), Europe (Italy, Spain, Germany, France, and Others), Asia-Pacific (India, China, Japan, South Korea, and Others), and the Rest of the World (the Middle East & Africa, and Latin America). The market can be analyzed for a particular region or country level as per the requirement. Among all regions, Europe has been significantly contributing to the market attributed to the increasing investments in the healthcare sector and the rising development of new drugs and therapeutics. In addition, the advancements in technology and favorable government policies and initiatives are projected to strengthen the leukemia market in Europe during the forecast period.
Global Leukemia Cancer Market Growth, by Region 2022-2028
The North America Region is Expected to hold the Significant Share in the Global Leukemia Cancer Market over the Forecast Period
The North American market for leukemia is expected to hold a significant share throughout the forecast period due to the high incidence rate of cancers in the US. For instance, according to the American Cancer Society, in 2020, there will be approximately 89,500 cancer cases diagnosed and about 9,270 cancer deaths in adolescents and young adults (AYAs) ages 15 to 39 years in the US. These patients are often grouped with younger or older patient populations
Market Players Outlook
The major companies serving the global leukemia cancer market include Bristol-Myers Squibb, Celgene Corp., Daiichi Sankyo Co., Ltd., F. Hoffmann-La Roche Ltd., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in April 2021, the immunotherapy drug blinatumomab (Blincyto) is more effective than chemotherapy in treating B-cell acute lymphoblastic leukemia (B-ALL) that has relapsed in children and young adults, results from two clinical trials that show.
The Report Covers
- Market value data analysis of 2021 and forecast to 2028.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global leukemia cancer market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
1. Report Summary
• Current Industry Analysis and Growth Potential Outlook
• Impact of COVID-19 on the Global Leukemia Cancer Market
• Recovery Scenario of Global Leukemia Cancer Market
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
1.2.2. By Region
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
3. Competitive Landscape
3.1. Key Company Analysis
3.1.1. Overview
3.1.2. Financial Analysis
3.1.3. SWOT Analysis
3.1.4. Recent Developments
3.2. Key Strategy Analysis
3.3. Impact of Covid-19 on Key Players
4. Market Segmentation
4.1. Global Leukemia Cancer Market by Type
4.1.1. Acute Myeloid Leukaemia (AML)
4.1.2. Chronic Myeloid Leukaemia (CML)
4.1.3. Acute Lymphoblastic Leukaemia (ALL)
4.1.4. Chronic Lymphocytic Leukaemia (CLL)
4.2. Global Leukemia Cancer Market by Diagnose and Monitor
4.2.1. Blood Tests
4.2.2. Bone Marrow Tests
4.2.3. Imaging Tests
4.2.4. Lymph Node Biopsy
4.2.5. Lumbar Puncture
4.2.6. Urine Tests
4.3. Global Leukemia Cancer Market by Treatment
4.3.1. Chemotherapy
4.3.2. Radiation Therapy
4.3.3. Targeted Therapy
4.3.4. Biological Therapy
4.3.5. Stem Cell Transplant
5. Regional Analysis
5.1. North America
5.1.1. United States
5.1.2. Canada
5.2. Europe
5.2.1. UK
5.2.2. Germany
5.2.3. Italy
5.2.4. Spain
5.2.5. France
5.2.6. Rest of Europe
5.3. Asia-Pacific
5.3.1. China
5.3.2. India
5.3.3. Japan
5.3.4. South Korea
5.3.5. Rest of Asia-Pacific
5.4. Rest of the World
6. Company Profiles
6.1. Actinium Pharmaceuticals Inc.
6.2. Biogen Idec Inc.
6.3. Bristol-Myers Squibb
6.4. Celgene Corp. (Bristol-Myers Squibb)
6.5. Daiichi Sankyo Co., Ltd.
6.6. Eisai Co. Ltd.
6.7. Epizyme Inc.
6.8. Erytech Pharma S.A.
6.9. F. Hoffmann-La Roche Ltd.
6.10. Genmab A/S
6.11. Glaxosmithkline Plc
6.12. Novartis International AG
6.13. Pfizer Inc.
6.14. Sanofi
6.15. Spectrum Pharmaceuticals Inc.
6.16. Viracta Therapeutics, Inc.
6.17. Takeda Oncology
6.18. Teva Pharmaceuticals Industries Ltd.
1. GLOBAL LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
2. GLOBAL ACUTE MYELOID LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
3. GLOBAL CHRONIC MYELOID LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
4. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
5. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
6. GLOBAL LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSE AND MONITOR, 2021-2028 ($ MILLION)
7. GLOBAL LEUKEMIA CANCER BY BLOOD TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
8. GLOBAL LEUKEMIA CANCER BY BONE MARROW TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
9. GLOBAL LEUKEMIA CANCER BY IMAGING TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
10. GLOBAL LEUKEMIA CANCER BY LYMPH NODE BIOPSY MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
11. GLOBAL LEUKEMIA CANCER BY LUMBAR PUNCTURE MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
12. GLOBAL LEUKEMIA CANCER BY URINE TESTS MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
13. GLOBAL LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
14. GLOBAL CHEMOTHERAPY FOR LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
15. GLOBAL RADIATION THERAPY FOR LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
16. GLOBAL TARGETED THERAPY FOR LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
17. GLOBAL BIOLOGICAL THERAPY FOR LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
18. GLOBAL STEAM CELL TRANSPLANT FOR LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY REGION, 2021-2028 ($ MILLION)
19. GLOBAL LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY GEOGRAPHY, 2021-2028 ($ MILLION)
20. NORTH AMERICAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
21. NORTH AMERICAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
22. NORTH AMERICAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSE AND MONITOR, 2021-2028 ($ MILLION)
23. NORTH AMERICAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
24. EUROPEAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
25. EUROPEAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
26. EUROPEAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSE AND MONITOR, 2021-2028 ($ MILLION)
27. EUROPEAN LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
28. ASIA-PACIFIC LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
29. ASIA-PACIFIC LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
30. ASIA-PACIFIC LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSE AND MONITOR, 2021-2028 ($ MILLION)
31. ASIA-PACIFIC LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
32. REST OF THE WORLD LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2021-2028 ($ MILLION)
33. REST OF THE WORLD LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TYPE, 2021-2028 ($ MILLION)
34. REST OF THE WORLD LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY DIAGNOSE AND MONITOR, 2021-2028 ($ MILLION)
35. REST OF THE WORLD LEUKEMIA CANCER MARKET RESEARCH AND ANALYSIS BY TREATMENT, 2021-2028 ($ MILLION)
1. IMPACT OF COVID-19 ON GLOBAL LEUKEMIA CANCER MARKET, 2021-2028 ($ MILLION)
2. IMPACT OF COVID-19 ON GLOBAL LEUKEMIA CANCER MARKET BY SEGMENT, 2021-2028 ($ MILLION)
3. RECOVERY OF GLOBAL LEUKEMIA CANCER MARKET, 2022-2028 (%)
4. GLOBAL LEUKEMIA CANCER MARKET SHARE BY TYPE, 2021 VS 2028 (%)
5. GLOBAL ACUTE MYELOID LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
6. GLOBAL CHRONIC MYELOID LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
7. GLOBAL ACUTE LYMPHOBLASTIC LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
8. GLOBAL CHRONIC LYMPHOCYTIC LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
9. GLOBAL LEUKEMIA CANCER MARKET SHARE BY DIAGNOSE AND MONITOR, 2021 VS 2028 (%)
10. GLOBAL LEUKEMIA CANCER BY BLOOD TESTS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
11. GLOBAL LEUKEMIA CANCER BY BONE MARROW TESTS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
12. GLOBAL LEUKEMIA CANCER BY IMAGING TESTS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
13. GLOBAL LEUKEMIA CANCER BY LYMPH NODE BIOPSY MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
14. GLOBAL LEUKEMIA CANCER BY LUMBAR PUNCTURE MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
15. GLOBAL LEUKEMIA CANCER BY URINE TESTS MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
16. GLOBAL CHEMOTHERAPY FOR LEUKEMIA CANCER MARKET SHARE BY TREATMENT, 2021 VS 2028 (%)
17. GLOBAL RADIATION THERAPY FOR LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
18. GLOBAL TARGETED THERAPY FOR LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
19. GLOBAL BIOLOGICAL THERAPY FOR LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
20. GLOBAL STEAM CELL TRANSCRIPT FOR LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
21. GLOBAL LEUKEMIA CANCER MARKET SHARE BY GEOGRAPHY, 2021 VS 2028 (%)
22. US LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
23. CANADA LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
24. UK LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
25. FRANCE LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
26. GERMANY LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
27. ITALY LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
28. SPAIN LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
29. REST OF EUROPE LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
30. INDIA LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
31. CHINA LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
32. JAPAN LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
33. SOUTH KOREA LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
34. REST OF ASIA-PACIFIC LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
35. REST OF THE WORLD LEUKEMIA CANCER MARKET SIZE, 2021-2028 ($ MILLION)
